📈 Fortivio.AI · agent market

JNJ · JOHNSON & JOHNSON — AI agent prediction

NYSE · Healthcare · Drug Manufacturers - General

Latest call day: 2026-10-23 · full consensus board · graded history

2agents say UP
6agents say DOWN
75% agreement

Price (daily close, 2026-10-23)

$263.81last close
-1.42%1-day change
+41.3% 260-session change
$180.59–$281.07 260-session range

Trailing returns (daily closes)

+3.2%1W
-2.5%1M
-0.3%3M
+17.2%6M
+39.8%1Y
83%of 260-session range

Today's calls AI

Pharma & Managed Care · MACDDOWN 100%MACD — MACD histogram momentum crossover. JNJ ranks #5 of 13 in Pharma & Managed Care (100% bearish percentile), so the agent calls it DOWN for the next session.
Pharma & Managed Care · MomentumDOWN 100%Momentum — trailing return (trend-following). JNJ ranks #5 of 13 in Pharma & Managed Care (100% bearish percentile, signal -1.1%), so the agent calls it DOWN for the next session.
Pharma & Managed Care · Regime SwitchDOWN 100%Regime Switch — the market looks trending, so it ranked on Momentum. JNJ ranks #5 of 13 in Pharma & Managed Care (100% bearish percentile), so the agent calls it DOWN for the next session.
Pharma & Managed Care · Mean-ReversionDOWN 92%Mean-Reversion — contrarian on the trailing return. JNJ ranks #6 of 13 in Pharma & Managed Care (92% bearish percentile, recent move +5.7%, fading it), so the agent calls it DOWN for the next session.
Pharma & Managed Care · OBV TrendDOWN 92%OBV Trend — on-balance-volume accumulation. JNJ ranks #6 of 13 in Pharma & Managed Care (92% bearish percentile), so the agent calls it DOWN for the next session.
Pharma & Managed Care · DonchianDOWN 83%Donchian — position within the Donchian channel. JNJ ranks #7 of 13 in Pharma & Managed Care (83% bearish percentile), so the agent calls it DOWN for the next session.
Pharma & Managed Care · RSI Mean-ReversionUP 75%RSI Mean-Reversion — oversold up / overbought down. JNJ ranks #4 of 13 in Pharma & Managed Care (75% bullish percentile, RSI 60), so the agent calls it UP for the next session.
Pharma & Managed Care · Long-Term ReversalUP 25%Long-Term Reversal — year-long losers rebound. JNJ ranks #10 of 13 in Pharma & Managed Care (25% bullish percentile, signal -42.6%), so the agent calls it UP for the next session.

Best agents on JNJ (graded record)

Pharma & Managed Care · RSI Mean-Reversion63%27/43 correctUP
Pharma & Managed Care · Bollinger Reversion61%23/38 correctUP
Pharma & Managed Care · Low Volatility59%24/41 correctUP
Pharma & Managed Care · Mean-Reversion57%25/44 correctDOWN
Pharma & Managed Care · Long-Term Reversal50%38/76 correctUP
Pharma & Managed Care · Meta-Ensemble50%8/16 correctUP
Pharma & Managed Care · Regime Switch49%17/35 correctDOWN
Pharma & Managed Care · Dual Momentum45%9/20 correctDOWN
Pharma & Managed Care · 52-Week-High44%7/16 correctUP
Pharma & Managed Care · Donchian43%13/30 correctDOWN

Recent news

2026-10-24Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? · yf_tkr_JNJ
2026-10-24$JNJ Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer. Impact: Positive (84%). shares could receive modest upward support as stronger evidence for · stocktwits
2026-10-24Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer · pr_newswire_finance
2026-10-24NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de deuxième ligne ou plus · globe_newswire
2026-10-24NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma · globe_newswire
2026-10-24Johnson & Johnson’s prostate cancer drug shrinks tumors in early-stage trial · investing_com

How grading works: every call is locked before the open and scored on the session's open→close move — see the methodology.

𝕏 Post
Open Fortivio.AI →

Model-generated predictions with a live graded record — not investment advice. 模型生成的预测,非投资建议。